The short version
Only one company currently supplies this market — there is no backup if it stumbles.
Market view
insulin aspart-fsan
2 marketed package NDCs · 1 active manufacturer
What changed in the last 90 days
Every detected change for insulin aspart-fsan, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.
Same drug class
Other molecules FDA puts in Insulin Analog, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
- attention deficit mild drops· 1 maker
- attention deficit severe drops· 1 maker
- dna insulin drops· 1 maker
- insulin aspart injection· 1 maker
- insulin aspart-xjhz· 1 maker
- insulin degludec and liraglutide· 1 maker
- insulin glargine and lixisenatide· 1 maker
- insulin glargine-aldy· 1 maker
- insulin glulisine· 1 maker
- pancreas db liquescence· 1 maker
- insulin· 2 makers
- insulin aspart-szjj· 2 makers
Common questions
- Is Insulin aspart-fsan in shortage right now?
- No. FDA does not currently list Insulin aspart-fsan in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Insulin aspart-fsan?
- 1 company has marketed Insulin aspart-fsan in the last 30 days, according to the FDA NDC Directory. That is a thin market — if one stops making it, supply is at risk quickly. Every manufacturer and package is listed on this page.
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.